Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 443

1.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
[PubMed - indexed for MEDLINE]
2.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
[PubMed - indexed for MEDLINE]
3.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
[PubMed - indexed for MEDLINE]
4.

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.

J Clin Psychiatry. 2008 Dec;69(12):1928-36. Epub 2008 Dec 2.

PMID:
19192475
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.

Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA, Carlson BX, Berman RM.

Int J Geriatr Psychiatry. 2011 Jun;26(6):564-72. doi: 10.1002/gps.2564. Epub 2010 Sep 9.

PMID:
20827794
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012;81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.

PMID:
22286203
[PubMed - indexed for MEDLINE]
7.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.

Nelson JC, Thase ME, Bellocchio EE, Rollin LM, Eudicone JM, McQuade RD, Marcus RN, Berman RM, Baker RA.

Int Clin Psychopharmacol. 2012 May;27(3):125-33. doi: 10.1097/YIC.0b013e3283502791.

PMID:
22466058
[PubMed - indexed for MEDLINE]
8.

Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.

Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, Nelson JC.

J Affect Disord. 2014 Jun;162:20-5. doi: 10.1016/j.jad.2014.03.017. Epub 2014 Mar 24.

PMID:
24766999
[PubMed - indexed for MEDLINE]
Free Article
9.

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.

Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):965-72. doi: 10.1002/pds.1805.

PMID:
19662630
[PubMed - indexed for MEDLINE]
10.

Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).

Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T; ADMIRE Study Group.

J Affect Disord. 2013 Dec;151(3):899-905. doi: 10.1016/j.jad.2013.07.035. Epub 2013 Aug 28.

PMID:
24074484
[PubMed - indexed for MEDLINE]
Free Article
11.

Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.

Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Tran QV, Berman RM, Carlson BX.

J Clin Psychiatry. 2011 Apr;72(4):548-55. doi: 10.4088/JCP.09m05495gre. Epub 2010 Aug 24.

PMID:
20816039
[PubMed - indexed for MEDLINE]
12.

Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.

Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R; Aripiprazole Study Group.

J Clin Psychiatry. 2007 Oct;68(10):1480-91.

PMID:
17960961
[PubMed - indexed for MEDLINE]
13.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
[PubMed - indexed for MEDLINE]
14.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.

Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ.

CNS Spectr. 2014 Dec;19(6):528-34. doi: 10.1017/S109285291300103X. Epub 2014 Mar 18.

PMID:
24642260
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
[PubMed - indexed for MEDLINE]
16.

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.

Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, Reeves RA.

J Psychopharmacol. 2010 Apr;24(4):537-46. doi: 10.1177/0269881108096522. Epub 2008 Oct 2.

PMID:
18832427
[PubMed - indexed for MEDLINE]
17.

Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.

Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.

J Clin Psychiatry. 2012 Mar;73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.

PMID:
21939613
[PubMed - indexed for MEDLINE]
18.

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.

Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R.

J Clin Psychopharmacol. 2008 Feb;28(1):13-20. doi: 10.1097/jcp.0b013e3181618eb4. Erratum in: J Clin Psychopharmacol. 2009 Feb;29(1):38.

PMID:
18204335
[PubMed - indexed for MEDLINE]
19.

Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.

Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E.

Int Clin Psychopharmacol. 2009 May;24(3):133-8. doi: 10.1097/YIC.0b013e3283277614.

PMID:
19318972
[PubMed - indexed for MEDLINE]
20.

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.

El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H.

Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.

PMID:
20175941
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk